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A patient with maculopapular
rash and lichenoid skin
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Abstract
Tyrosine kinase inhibitors (TKIs) are invaluable for the treatment of patients with chronic mye-
logenous leukemia. Although TKIs are generally better tolerated than traditional chemotherapy,
dermatologic side effects are common and present a significant cause of concern for both
patients and physicians. Ponatinib is a third-generation TKI and the only kinase inhibitor effective
in patients with certain BCR-ABL1 mutations, including the T315I mutation. However, ponatinib is
associated with an increased risk of serious side effects, and severe cutaneous reactions have
increasingly been reported. We present a patient who developed a cutaneous lichenoid eruption
following the initiation of ponatinib, which resolved after treatment with a topical retinoid. This
case demonstrates that cutaneous side effects caused by ponatinib can be managed relatively
easily, allowing patients to continue treatment with ponatinib. This is important considerting the
limited alternative treatment approaches available for BCR-ABL1 T315I chronic myelogenous
leukemia.
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Introduction
Ponatinib is a third-generation tyrosine kinase
inhibitor (TKI) approved for the treatment of
Philadelphia chromosome-positive leukemia,
including patients with BCR-ABL1 kinase
mutations such as T315I, which confers pan-
resistance to first- and second-generation
TKIs.1–3 Ponatinib treatment is associated
with risks of severe side effects, including
hypertension, arterial and venous thrombosis,
cardiac failure, congestive heart failure, pleu-
ral effusion, and severe bone marrow depres-
sion. Dermatological adverse reactions,
typically including non-specific cutaneous
eruptions, are also common and rashes with
varying histopathological patterns have
recently been reported in association with
ponatinib treatment. We present a patient
who developed a lichenoid cutaneous eruption
following the initiation of ponatinib, but who
recovered after treatment with a
topical retinoid.
Case report
A 45-year-old male patient diagnosed with
Philadelphia chromosome-positive chronic
myelogenous leukemia (CML) started treat-
ment with the first-generation TKI imati-
nib, which was well tolerated. However,
after an initial optimal response, his BCR-
ABL1/ABL1 transcript ratio started to
increase after 15 months. Failure of imati-
nib treatment was suspected, and BCR-
ABL1 mutation analysis confirmed the
BCR-ABL1 T315I mutation. The T315I
mutation is associated with resistance to
conventional TKIs, with ponatinib the
only TKI with a documented effect against
this BCR-ABL1 mutation.1,3 Treatment
with ponatinib was therefore initiated.
The patient achieved cytogenetic remission
after 4 months of treatment, and his initial
dose of 30 mg was reduced to 15 mg/day. He
also received acetylsalicylic acid 75 mg/day
for thrombosis prophylaxis.
The patient started to complain of pru-
ritus and skin irritation after treatment with
ponatinib for 6 months, although no clear
rash was seen during clinical examination.
However, 3 months later, after 9 months of
ponatinib therapy, the patient developed a
non-specific maculopapular rash with some
comedones, most prominent on his front
torso (Figure 1). Skin biopsy demonstrated
a mild lichenoid reaction with scattered epi-
dermal basal cell vacuolization and some
civatte bodies (Figure 2). There were no
eosinophilic granulocytes. Mild chronic
perivascular inflammation was seen in the
upper dermis, not associated with the fol-
licles. Based on these findings, a drug-
related reaction could not be ruled out.
Based on the available literature4 and in
cooperation with a local dermatologist,
treatment with the third-generation topical
retinoid adapalene, and the bactericidal
oxidizing compound benzoyl peroxide was
initiated. The patient responded to the
treatment with recovery of the skin lesions
and reduced pruritus.
Figure 1. Patient’s front torso demonstrating
general maculopapular rash with some comedones.
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Written consent was obtained from the
patient for publication of this case report.
Discussion
Cutaneous eruptions are common side
effects of all TKIs used in the treatment of
leukemia.4 In phase II clinical trials, 39% of
patients with CML treated with ponatinib
developed a rash. Most of these emerged
within 3 months of treatment, but some
reactions did not develop until 24 months
after therapy initiation.5 Published case
reports have described lamellar ichthyosis-
like, keratosis pilaris-like, lichen plano-
pilaris-like, and pityriasis rubra pilaris-like
eruptions, as well as folliculocentric and
seborrheic changes after the initiation of
ponatinib.6–11 Suggested treatment options
for these skin reactions include topical ste-
roids, retinoids, keratolytics, and antifun-
gals, as well as systemic retinoids in more
severe cases.4 Unlike the current patient,
most previously reported cases described
an ichthyosiform appearance, as well as fol-
licular involvement on histopathological
examination. It is possible that the early
identification and treatment of the condi-
tion in the present case prevented its further
development into a more severe dermato-
logical reaction. This and previous cases
demonstrate that topical retinoids may be
efficient for treating a wide range of cuta-
neous reactions associated with ponatinib,
including lichenoid eruptions. However, the
mechanisms responsible for the dermato-
logic side effects of ponatinib, and the
potential therapeutic effects of retinoids
have yet to be established. Some researchers
have suggested that retinoids may strength-
en the local chemotherapeutic resistance of
keratinocytes by upregulating heparin-
binding epidermal growth factor.7
Dermatological adverse reactions are
common after treatment with TKIs. The
impacts of these side effects on the patient’s
appearance and quality of life may ultimately
lead to interruption of their anticancer thera-
py. The current case demonstrates that lichen-
oid cutaneous eruptions caused by ponatinib
may be treated with topical retinoids, support-
ing the hypothesis that retinoids possibly
increase the local chemotherapeutic resistance
of keratinocytes. We therefore conclude that
some of the cutaneous effects of ponatinib
may be alleviated by topical retinoids, possi-
bly allowing life-saving anticancer therapy to
be continued in more patients.
Figure 2. Skin biopsy at low magnification (a) and high magnification (b) demonstrating thin epidermis and
signs of mild lichenoid damage with sparse vacuolization, and a few civatte bodies; mild chronic perivascular
inflammatory infiltrate predominantly in the upper dermis; no eosinophilic granulocytes. Scale bars about
400 mm (a) and about 70 mm (b).
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